Press Release

REVOLUTION Medicines Raises $56 Million Series B Financing

Redwood City, CA – April 24, 2018 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced it has raised $56 million in a Series B financing to support its ongoing R&D programs…

Read more

Press Release

Revolution Medicines Appoints Vincent Miller, M.D. to Board of Directors

Redwood City, CA –October 5, 2017 – REVOLUTION Medicines, Inc., a drug discovery and development company focused on frontier cancer targets, today announced the appointment of Vincent Miller, M.D., to its board of directors. Dr. Miller is a leader…

Read more

Press Release

Revolution Medicines Reports Discovery that May Expand Range of Clinically Actionable Cancer Mutations

Redwood City, CA –September 14, 2017 – REVOLUTION Medicines, Inc., a company focused on frontier cancer targets and drug discovery, today published a report entitled “Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling…

Read more

Publication

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

New research revealed an unexpected dependence of some cancer-causing forms of proteins in the RAS-MAP kinase pathway on the normal biochemical actions of SHP2.  These functions can be disrupted by small molecule inhibitors of SHP2 designed by the…

Read more